EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study

Marta Miarons iD, Alba Manzaneque Gordón, Pau Riera, Fernando Gutiérrez Nicolás, RedDPYD Research Group with the Spanish Society of Hospital Pharmacy (SEFH)

The Oncologist · 08.05.2023 · 28 (5) · e304-e308

DOI: 10.1093/oncolo/oyad077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 04.04.2023. Verfasst von Marta Miarons und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital, Campus, Barcelona, Spain. Hauptthemen laut MEDLINE: Dihydrouracil Dehydrogenase (NADP), Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Identifying polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) gene is gaining importance to be able to predict fluoropyrimidine-associated toxicity. The aim of this project was to describe the frequency of the DPYD variants DPYD*2A (rs3918290); c.1679T>G (rs55886062); c.2846A>T (rs67376798) and c.1129-5923C>G (rs75017182; HapB3) in the Spanish oncological patients. Material and Methods Cross-sectional and multicentric study (PhotoDPYD study) conducted in hospitals located in Spain designed to register the frequency of the most relevant DPYD genetic variants in oncological patients. All oncological patients with DPYD genotype were recruited in the participant hospitals. The measures determined where the presence or not of the 4 DPYD previously described variants.

Results

Blood samples from 8054 patients with cancer from 40 different hospitals were used to determine the prevalence of the 4 variants located in the DPYD gene. The frequency of carriers of one defective DPYD variant was 4.9%. The most frequently identified variant was c.1129-5923C>G (rs75017182) (HapB3), in 2.9%, followed by c.2846A>T (rs67376798) in 1.4%, c.1905 + 1G>A (rs3918290, DPYD*2A) in 0.7% and c.1679T>G (rs55886062) in 0.2% of the patients. Only 7 patients (0.08%) were carrying the c.1129-5923C>G (rs75017182) (HapB3) variant, 3 (0.04%) the c.1905 + 1G>A (rs3918290, DPYD*2A) and one (0.01%) the DPYD c.2846A>T (rs67376798, p.D949V) variant in homozygosis. Moreover, 0.07% were compound heterozygous patients, 3 carrying the DPYD variants DPYD*2A + c.2846A>T, 2 the DPYD c.1129-5923C>G + c.2846A>T and one the DPYD*2A + c.1129-5923C>G variants.

Conclusions

Our results demonstrate the relatively high frequency of DPYD genetic variants in the Spanish patient with cancer population, which highlights the relevance of their determination before initiating a fluoropirimidine-containing regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dihydrouracil Dehydrogenase (NADP)NeoplasmsHumansCross-Sectional StudiesFluorouracilGenotypePolymorphism, GeneticSpain

Substanzen

Dihydrouracil Dehydrogenase (NADP)Fluorouracil

Autor:innen und Institutionen

  • Pharmacy Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital, Campus, Barcelona, Spain.
  • ReDPyD group from the Spanish Society of Hospital Pharmacy (SEFH), Tenerife, Canarias, Spain.
  • Pharmacy Department, Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain.
  • Pharmacy Department, IIB-Sant Pau, Hospital de la Santa Creu i Sant Pau, Carrer Sant Quintí, Barcelona, Spain.
  • U705, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain.
  • Pharmacy Department, Research Unit Hospital Universitario de Canarias (CHUC), Tenerife, Canarias, Spain.

ORCID-Profile: Marta Miarons

Zitieren

APA

Miarons, M., Manzaneque Gordón, A., Riera, P., Gutiérrez Nicolás, F., & RedDPYD Research Group with the Spanish Society of Hospital Pharmacy (SEFH) (2023). Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study. The Oncologist, 28(5), e304-e308. https://doi.org/10.1093/oncolo/oyad077

Vancouver

Miarons M, Manzaneque Gordón A, Riera P, Gutiérrez Nicolás F, RedDPYD Research Group with the Spanish Society of Hospital Pharmacy (SEFH). Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study. The Oncologist. 2023;28(5):e304-e308. doi:10.1093/oncolo/oyad077

BibTeX
@article{Miarons2023,
  author = {Miarons, Marta and Manzaneque Gordón, Alba and Riera, Pau and Gutiérrez Nicolás, Fernando and RedDPYD Research Group with the Spanish Society of Hospital Pharmacy (SEFH), RedDPYD Research Group with the Spanish Society of Hospital Pharmacy (SEFH)},
  title = {Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study},
  journal = {The Oncologist},
  year = {2023},
  volume = {28},
  number = {5},
  pages = {e304--e308},
  doi = {10.1093/oncolo/oyad077}
}
Kostenlos starten →